Mereo BioPharma Group (MREO)
NASDAQ: MREO
· Real-Time Price · USD
2.04
-0.01 (-0.49%)
At close: Oct 03, 2025, 3:59 PM
2.06
0.98%
After-hours: Oct 03, 2025, 05:54 PM EDT
-0.49% (1D)
| Bid | 1.93 |
| Market Cap | 322.52M |
| Revenue (ttm) | 1.56M |
| Net Income (ttm) | -49.55M |
| EPS (ttm) | -0.3 |
| PE Ratio (ttm) | -6.8 |
| Forward PE | -68.33 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 2.1 |
| Volume | 1,334,380 |
| Avg. Volume (20D) | 2,289,468 |
| Open | 2.07 |
| Previous Close | 2.05 |
| Day's Range | 1.97 - 2.13 |
| 52-Week Range | 1.47 - 4.72 |
| Beta | 0.39 |
| Ex-Dividend Date | n/a |
About MREO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MREO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MREO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsMereo BioPharma Group is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-42.52%
Mereo BioPharma Group shares are trading lower aft...
Unlock content with
Pro Subscription
6 months ago
+1.69%
Mereo BioPharma shares are trading higher after JP Morgan initiated coverage on the stock with an Overweight rating and announced a price target of $7.
2 months ago · seekingalpha.com
Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OIMereo BioPharma Group plc's phase 3 ORBIT study for setrusumab in osteogenesis imperfecta will continue to final analysis, expected by end of 2025. The recent 35% MREO stock drop was due to not meetin...
